NanoRepro AG
XTRA:NN6
Germany / Healthcare / Healthcare Equipment & Supplies
Exchange Data
Hide this widget
Price
1.35 EUR
Day change
0.03 (1.89%)
52-week range
1.24 - 2.25
11:38 PM - Closed
Summary of NanoRepro AG
Hide this widget
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internat...
Next Earnings
Jun 6, 2025
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
0.07 (5.47%)
Data Explorer
Hide this widget
Search metric that you want to observe. Create your own widget, customise and rearrange metrics
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| NN6 | Peers | Sector | |
|---|---|---|---|
Market Cap | 17.028 M | 44.896 M | 55.991 M |
Price % of 52 Week High | Premium | 71.4% | 60.3% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -3.5% | -0.7% |
1 Year Price Total Return | -22.4% | -19.1% | -12.3% |
Beta (5 Year) | -0.17 | 0.77 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for NanoRepro is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for NanoRepro AG
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 6 hours ago |
| Earnings Power ValueView Updated 16 hours ago |
| 10Y Historical FinancialsView Updated 6 hours ago |
| 5Y Historical FinancialsView Updated 6 hours ago |
| EV / EBIT MultiplesView Updated 16 hours ago |
| EV / EBITDA MultiplesView Updated 16 hours ago |
| P/E MultiplesView Updated 16 hours ago |
| Price / Book MultiplesView Updated 16 hours ago |
| Price / Sales MultiplesView Updated 16 hours ago |
| EV / Revenue MultiplesView Updated 16 hours ago |
| CAPM WACC ModelView Updated 21 hours ago |
| 10Y DCF EBITDA ExitView Updated 16 hours ago |
| 10Y DCF Revenue ExitView Updated 16 hours ago |
| 10Y DCF Growth ExitView Updated 16 hours ago |
| 5Y DCF EBITDA ExitView Updated 16 hours ago |
| 5Y DCF Revenue ExitView Updated 16 hours ago |
| 5Y DCF Growth ExitView Updated 16 hours ago |
Historical Financials
Full Financials
Hide this widget
| (EUR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Jun-24 | Jun-23 | Jun-24 |
| Income Statement | |||||
| Revenue | 39 | 3.18 | 3.56 | 0.70 | 0.89 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | (4.52) | (5.32) | (4.79) | (1.39) | (1.12) |
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | 13 | (10) | - | (0.07) | - |
Analyst Notes
April 20, 2025
Hide this widget